Original release date: September 26, 2022
Access to this course expires on:  September 12, 2025 at 11:59 PM Pacific Time
CME 11.5

Course Description
Accurate diagnosis in hematopathology relies heavily on the complex integration of data from clinical presentation, conventional microscopy, immunohistochemistry, flow cytometry, and molecular and cytogenetic analyses. Diagnosis is often complicated by the fact that clinically relevant disease subsets can share overlapping diagnostic features, and both baseline appreciation for disease spectrum and appropriate application/interpretation of ancillary testing is lacking. This gap can lead to real and immediate clinical consequences for therapeutic selection and overall patient management.

While in-house testing for the vast array of available diagnostic, prognostic and predictive markers is not possible in every setting or practice, awareness of their applicability and impact on patient care is the responsibility of both the pathologist and treating clinician. This is particularly true in an era when patients are increasingly knowledgeable about genomic and proteomic analyses and the studies are easily accessible. Approaching this target by strengthening baseline knowledge and skill in application empowers the pathologist as a consultant to the clinical care team.

Target Audience

Practicing academic and community pathologists, and pathologists-in-training

Learning Objectives

Upon completion of this educational activity, learners will be able to:

• Describe the limitations of the current diagnostic approach to hematolymphoid neoplasms in the revised WHO classification and mutational data
• Review pitfalls in common lymphoma diagnosis seen in clinical practice
• Apply molecular testing in the work-up of myeloid malignancies and integration of results into clinical practice and diagnosis
• Review novel and prognostic biomarkers relevant to the daily clinical practice
• Describe diagnostic pathologic criteria for indolent lymphoproliferations

Continuing Medical Education

The United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The United States and Canadian Academy of Pathology designates this enduring material for a maximum of 11.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to USCAP and to learners any financial relationship(s) that have occurred within the last 24 months with any commercial interest(s) whose products or services are related to the CME content. USCAP has reviewed all disclosures and mitigated all identified conflicts of interest, as applicable.

The following faculty reported no relevant financial relationships: The following faculty reported no relevant financial relationships: Olga K. Weinberg, MD, Yuri Fedoriw, MD, Elaine S. Jaffe, MD, Kaaren Reichard, MD

The following IM Coordinator who planned and reviewed content for this activity reported no relevant financial relationships: Daniel A. Arber, MD

USCAP staff associated with the development of content for this activity reported no relevant financial relationships.

---

To earn CME credit, all learners must complete the evaluation. View and print your certificate by clicking here.

USCAP members receive a discount on this activity. Not A Member? Click Here!